drugset / Trial / NCT01648179

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

NCT01648179

Phase 1 Completed 24 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study is an open-label, randomized, single dose, four period, balanced crossover study to assess in eligible healthy male or female subjects.

Timeline

Start
2012-03
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject LANOPEPDEN Small molecule 1500 mg Intravenous